Telix Pharmaceuticals Logo
AU000000TLX2
A2H7JK
TLPPF

Telix Pharmaceuticals

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Telix uses imaging revenue scaling to fund and accelerate its pipeline

    Telix reports that the imaging business generates around $1 billion in annual revenue and funds research and development. The company received FDA approval for PIXCLARA, expanding its commercial portfolio to three products and expects launch revenues of “a few hundred million” US dollars. Recruitment for the BiPASS phase-III study is complete, and three phase-III therapy programs are also recruiting, including ProstACT GLOBAL 2 with TLX591 and the novel TLX597. Management sees 2026 guidance toward the upper end of the range but remains cautious about making adjustments given the market environment. » More on de.investing.com


  • Telix Pharmaceuticals: FDA approval for Pixclara drives stock up more than 10%

    Telix shares rose 10.3% to A$18.03 after the FDA approved the PET imaging agent Pixclara (floretyrosin F 18) to distinguish recurrent from progressive gliomas. The approval makes Telix the sole holder of an FDA‑approved radiopharmaceutical imaging agent for this indication. The approval opens significant commercial opportunities, as gliomas account for about 30% of brain and CNS tumors and roughly 80% of malignant brain tumors. Additional momentum came from management presentations at an investor conference; Telix reported H1 2026 revenue of USD 477 million (+22%), adjusted EBITDA up 146%, and raised its full‑year guidance to over USD 1 billion. » More on de.investing.com


  • Telix outlines strategy to dominate radiopharma market

    Telix presented at the Morgan Stanley Healthcare Conference an integrated strategy that links imaging diagnostics with therapeutic radiopharmaceuticals and seeks vertical control over manufacturing, logistics and patient selection. The company reported around AUD 1 billion in annual revenue, multiple approvals including Pixclara for gliomas, and named near-term catalysts such as the re-submission of Zircaix, completed recruitment of the BiPASS study and an interim analysis for TLX591. Telix is expanding its own nuclear pharmacies, acquired RLS to strengthen logistics, and sees significant growth potential in prostate cancer diagnostics as well as in late-stage programs for prostate, kidney and neurological indications. » More on de.investing.com


  • FDA grants Telix approval for glioma PET imaging agent Pixclara

    The FDA has approved Pixclara (floretyrosine F 18) from Telix for PET imaging to help distinguish recurrent or progressive gliomas from treatment-related changes in adults and children from one month of age. The intravenously administered radiotracer targets the membrane transport proteins LAT1 and LAT2; safety was evaluated in 382 patients, with headaches reported in ≥0.5% of patients. Telix is also running a phase 3 study for use in brain metastases and already markets Illuccix and Gozellix; three other investigational agents are in approval‑relevant studies. » More on de.investing.com


  • Telix Pharmaceuticals rises after FDA approval for PET imaging of brain tumors

    The FDA approved Pixclara, an amino-acid–based PET imaging agent for gliomas, making it the first radiopharmaceutical imaging product authorized by the agency for this indication. The stock rose intraday by as much as 12%. Pixclara targets an estimated 24,000 new diagnoses annually in the U.S. Telix reported group revenue of $477 million in the first half of 2026 (up 22% year‑on‑year), adjusted EBITDA that increased 146%, and an improved gross margin of 55%. » More on de.investing.com

Financials

In the last quarter, Telix Pharmaceuticals had revenue of €409.93M and net profit of €32.92M
(EUR) June 2026
YoY
Revenue 409.93M -
Gross profit 211.46M -
Net profit 32.92M -
EBITDA 10.26M -

Fundamentals

Metric Value
Market capitalization
€2.78B
Number of shares
339.78M
52-week high/low
€11.15 - €5.06
Dividends No
Beta
0.56
P/E ratio
94.60
PEG ratio
-0.42
P/B ratio
6.29
P/S ratio
3.47

Company profile

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Name
Telix Pharmaceuticals
CEO
Christian Behrenbruch
Headquarters North Melbourne, vic
Australia
Website
Sector
Health Care
Industry
Biotechnology
IPO
11/14/2017
Employees 1,152

Ticker symbols

Exchange Symbol
Pnk
TLPPF
Australian Securities Exchange Ltd
TLX.AX
Frankfurt
T3X.F
MĂĽnchen
T3X.MU
DĂĽsseldorf
T3X.DU
🍪

Parqet  uses cookies. Learn more